



Florida/Caribbean AIDS Education and Training Center

HIV CareLink

A Newsletter for HIV/AIDS Primary Care Providers

ABOUT US

The Florida/Caribbean AIDS Education and Training Center provides state-of-the-art HIV education, consultation, and resource materials to health care providers in Florida, Puerto Rico and the US Virgin Islands.

Major funding is provided by the US Public Health Service's Health Resources Services Administration (HRSA) DHHS-HAB Grant No. H4AHA00049 through the University of South Florida Center for HIV Education and Research, Michael Knox, PhD, Director.

EDITORS

Jeffrey Beal, MD, AAHIVS
(239) 839-4645
aetcbear@embarqmail.com

Joanne J. Orrick, PharmD, AAHIVE
(352) 273-7845
orricjj@ufl.edu

PEDIATRIC EDITOR

Belinda Beauchamp, MD
(787) 281-8501
belinda.beauchamp@upr.edu

MANAGING EDITOR

Kimberly Molnar, MAcc
(813) 974-4430
kmolnar@usf.edu

Volume 11 - Issue 5

August 20, 2010

Antiretroviral Safety-related Labeling Changes and FDA Communications

Joanne J. Orrick, PharmD, AAHIVE

Clinical Assistant Professor, University of Florida, Gainesville
Faculty and Training Coordinator, Florida/Caribbean AETC

This issue of *HIV Carelink* summarizes safety-related labeling changes and FDA Safety Alerts that have been released for antiretroviral agents over the past several months. The reader is encouraged to review the information in more detail on the FDA website and/or in the product labeling for each affected antiretroviral agent. A monthly list of safety-related labeling changes (often including links to the updated package insert) can be found on the [FDA website](#).

Generic	Brand	Date	Update(s)
Raltegravir	Isentress®	Jan '09 July '09	<ul style="list-style-type: none"> Adverse Reactions: Reports of depression, suicidal ideation, paranoia, and anxiety.
Abacavir	Epzicom® Trizivir® Ziagen®	Mar '09	<ul style="list-style-type: none"> Black box warning: HLA –B*5701 prior to use and avoid in pts who test (+). Permanently discontinue if hypersensitivity reaction cannot be ruled out regardless of HLA status. Precautions: Use of abacavir within previous 6 months associated with ↑ risk of MI in one published study. ↑ not seen in pooled analysis of trials. Data inconclusive. Consider coronary heart disease risk when prescribing ARVs including abacavir.
Lopinavir/ ritonavir	Kaletra®	Apr '09	<ul style="list-style-type: none"> Warnings/Precautions: PR interval prolongation and cases of 2° and 3° AV block. QT interval prolongation; isolated cases of torsade de pointes (causality not established).
Didanosine	Videx® Videx EC®	June '09	<ul style="list-style-type: none"> Contraindications: Due to ↑ exposure to didanosine and/or its active metabolite, didanosine is contraindicated with allopurinol or ribavirin.
Darunavir	Prezista®	June '09	<ul style="list-style-type: none"> Drug Interactions: ↑ buprenorphine active metabolite; clinical monitoring recommended when combined with buprenorphine ± naloxone; no dosage adjustments recommended.
Tipranavir	Aptivus®	June '09	<ul style="list-style-type: none"> Drug Interactions: <ul style="list-style-type: none"> Enfuvirtide (T-20): Tipranavir C_{min} ↑ 45% in pts receiving with T-20 in Phase III trials. Calcium channel blockers: caution and monitoring recommended. Buprenorphine/naloxone: Tipranavir C_{min} ↓ 40%.
Fosamprenavir	Lexiva®	Sept '09	<ul style="list-style-type: none"> Warnings/Precautions: ↑ in cholesterol added to lipid elevation section. Cases of nephrolithiasis reported during post-marketing surveillance.
Efavirenz	Sustiva® Atripla®	Sept '09	<ul style="list-style-type: none"> Warnings/Precautions: Reports of contraceptive failure in pts receiving efavirenz with implantable hormonal contraceptive; potential for interaction (induction of metabolism) with immunosuppressants metabolized by CYP3A4 (cyclosporine, sirolimus, tacrolimus).

For more information,
please visit our website:

www.FCAETC.org

To request clinical consultation, please call the
National Clinicians' Consultation Hotline:

1-800-933-3413

Generic	Brand	Date	Update(s)
Etravirine	Intelence®	Sept '09	<ul style="list-style-type: none"> Warnings/Precautions: Severe, potentially life-threatening, and fatal skin reactions (e.g. Stevens-Johnson Syndrome, toxic epidermal necrolysis, and erythema multiforme) and severe hypersensitivity reactions including hepatic failure have been reported.
Tenofovir	Viread® Truvada® Atripla®	Oct '09	<ul style="list-style-type: none"> Warnings: New onset or worsening renal impairment; routinely monitor CrCL.
Raltegravir	Isentress®	Nov '09	<ul style="list-style-type: none"> Adverse Reactions: Post-marketing reports of thrombocytopenia.
Ritonavir	Norvir®	Nov '09	<p>Drug interactions:</p> <ul style="list-style-type: none"> Contraindications: Use of sildenafil (Revatio®) when used for treatment pulmonary arterial hypertension contraindicated with ritonavir. Precautions: Due to ↑ levels of fluticasone propionate (Flonase®, Flovent®), should only be combined if benefits > risks.
Lopinavir /ritonavir	Kaletra®	Jan '10	<p>Drug interactions:</p> <ul style="list-style-type: none"> Due to ↑ risk of CV events (e.g. QT prolongation, palpitations, sinus tachycardia), should not be combined with salmeterol (Serevent®, Advair®). Contraindications: Use of sildenafil (Revatio®) when used for treatment pulmonary arterial hypertension contraindicated with lopinavir/ritonavir.
Didanosine	Videx® Videx EC®	Jan '10	<ul style="list-style-type: none"> Warnings/precautions: post-marketing cases of non-cirrhotic portal hypertension sometimes leading to liver transplant or death.
Nevirapine	Viramune®	Jan '10	<ul style="list-style-type: none"> Drug Interactions: Updates include interactions with atazanavir/r (↓ ATV, do not combine), darunavir/r (DRV C_{min} ↓ 21% to ↑ 32%), fosamprenavir/± r (↓ APV, do not combine), maraviroc (use standard dose NVP with MVC 300 mg bid).
Atazanavir	Reyataz®	Jan '10	<ul style="list-style-type: none"> Drug interactions: Updates include data on interactions between atazanavir ± ritonavir and rifabutin (↑ rifabutin levels) or buprenorphine (↑ buprenorphine levels).
Etravirine	Intelence®	Feb '10	<ul style="list-style-type: none"> Drug Interactions: Updates include data on interactions with fluconazole, voriconazole (both ↑ ETR levels, voriconazole levels ↑, no change in fluconazole levels), clopidogrel (↓ clopidogrel levels), lopinavir/ritonavir (↓ ETR but similar to reductions seen with DRV/r so no dosage adjustments recommended).
Saquinavir	Invirase®	Feb '10	<ul style="list-style-type: none"> FDA Safety Alert: FDA conducting ongoing safety review regarding prolongation of QT and PR interval with saquinavir/ritonavir. Should not be used in pts with history of QT prolongation, pre-existing conduction disease, ischemic heart disease, cardiomyopathy, or underlying structural heart disease. Do not use with Class IA (e.g. quinidine) or Class III (e.g. amiodarone) antiarrhythmics.
Raltegravir	Isentress®	Mar '10	<ul style="list-style-type: none"> Adverse Reactions: Post-marketing reports of rhabdomyolysis.

The complete collection of previous issues of HIV CareLink are available online.

To view past issues, please visit the archives at:

www.FCAETC.org/Newsletter

Generic	Brand	Date	Update(s)
All protease inhibitors		Apr '10	Drug Interactions: <ul style="list-style-type: none"> Contraindications: Use of sildenafil (Revatio®) when used for treatment pulmonary arterial hypertension; use of alfuzosin. Precautions: <ul style="list-style-type: none"> New dosing recommendation for bosentan (Tracleer®) and tadalafil (Adcirca®) when prescribed for the treatment of pulmonary arterial hypertension. Due to ↑ risk of CV events (e.g. QT prolongation, palpitations, and sinus tachycardia), salmeterol (Serevent®, Advair®) should not be co-administered with PIs. Colchicine: New dosage recommendations when prescribed for gout (treatment or prophylaxis) or familial Mediterranean fever; Recommendation to not use with PIs in pts with renal or hepatic impairment.
Maraviroc	Selzentry®	May '10	<ul style="list-style-type: none"> Contraindications: Should not be used in pts with CrCL < 30 mL/min who are taking potent CYP3A inhibitors or inducers. Warnings/Precautions: Pts with renal impairment are at ↑ for CV adverse events related to postural hypotension. Use in pts with CrCL < 30 mL/min only if not receiving potent CYP3A inhibitors or inducers and no alternative options are available. If pt experiences postural hypotension while receiving MVC 300 mg bid, ↓ MVC dose to 150 mg bid.
Lopinavir/ritonavir	Kaletra®	June '10	<ul style="list-style-type: none"> Drug interactions: Updates include potential for lopinavir/ritonavir to ↑ levels of fentanyl, nilotinib, dasatinib. Contraindications: Contraindicated in patients with previous hypersensitivity (e.g. Toxic epidermal necrolysis)

References:

1. FDA Medwatch. Medical Product Safety Information. Drug Safety Labeling Changes. <http://www.fda.gov/Safety/MedWatch/SafetyInformation/Safety-RelatedDrugLabelingChanges/default.htm>. Accessed August 9th, 2010.
2. FDA Medwatch. Medical Product Safety Information. Safety Alerts for Human Medical Products.. <http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm201563.htm>. Accessed April 2nd, 20'10.
3. FDA Medwatch. Medical Product Safety Information. May 20'10 Drug Safety Labeling Changes. <http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm214902.htm>. Accessed June 21st, 20'10.

Keeping With the Pace 2010:

An HIV/AIDS Update

Wednesday, September 1st, 2010

12:30 - 4:45 PM

Alachua County Health Department - Gainesville, Florida
or online via web video conferencing!

Pre-registration required.

Deadline - August 30, 2010

www.FCAETC.org/KWP

The complete collection of previous issues of HIV CareLink are available online.

To view past issues, please visit the archives at:

www.FCAETC.org/Newsletter